19 Jan 2023 • Published on the 18th of January, 2023 The drug regulator, Drugs Controller General of India (DCGI), has approved Covovax as a heterologous booster dose for adults administered with two doses of Covishield or Covaxin. According to official sources, the Serum Institute of India (SII) had written a letter to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax on the CoWIN portal as a heterologous booster dose for adults to boost uptake of booster doses. On January 16 the DCGI approved market authorisation for the Serum Institute of India COVID jab Covovax as a heterologous booster dose. Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorization. It was granted an emergency-use listing by the World Health Organization (WHO) on December 17, 2021. Recently, Bharat Biotech’s nasal Covid vaccine for adults above 18 years old was also approved by the Government of India and will be used as a heterologous booster dose as well. Source: The Print| Read full story